Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Other financing activities (2024 - 2025)

Prelude Therapeutics' Other financing activities history spans 2 years, with the latest figure at $1.8 million for Q4 2025.

  • For Q4 2025, Other financing activities rose 110.56% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $11.9 million, up 10730.0%, while the annual FY2025 figure was $11.9 million, 10730.0% up from the prior year.
  • Other financing activities for Q4 2025 was $1.8 million at Prelude Therapeutics, down from $2.4 million in the prior quarter.
  • Across five years, Other financing activities topped out at $6.1 million in Q2 2024 and bottomed at -$17.5 million in Q4 2024.